Factor VII Antibody (MA-HFVII): sc-81679

Factor VII Antibody (MA-HFVII) is a mouse monoclonal IgG1 antibody that detects Factor VII in human samples through western blotting (WB). Factor VII, also known as serum prothrombin conversion accelerator, proconvertin, or coagulation factor 7, is a crucial component in the hemostatic process, playing a vital role in the blood coagulation cascade. This 406 amino acid protein is synthesized in the liver as an inactive precursor and requires vitamin K for activity. Upon tissue injury, Factor VII is activated through proteolytic cleavage by Factor IX A, Factor X A, Factor XII A, or thrombin, resulting in the formation of Factor VII A, an active serine protease. Factor VII A consists of a heavy chain linked by disulfide bonds to a light chain, which contains two epidermal growth factor (EGF)-like domains. These domains are essential for Factor VII′s interaction with other coagulation factors, facilitating the conversion of prothrombin to thrombin, a key step in clot formation. Understanding Factor VII′s structure and function is critical, as deficiencies or mutations at the F7 locus can lead to bleeding disorders, although many individuals remain asymptomatic or exhibit uncharacterized phenotypes. Factor VII (MA-HFVII) antibody is an invaluable tool for researchers studying coagulation pathways and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Factor VII Antibody (MA-HFVII) References:

1. Novel mutations in the Factor VII gene of Taiwanese Factor VII-deficient patients.  |  Shen, MC., et al. 2001. Br J Haematol. 112: 566-71. PMID: 11260055
2. Fibrinogen and factor VII promoter polymorphisms in women with preeclampsia.  |  Laasanen, J., et al. 2002. Obstet Gynecol. 100: 317-20. PMID: 12151156
3. Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas.  |  Giansily-Blaizot, M., et al. 2003. Pathophysiol Haemost Thromb. 33: 36-42. PMID: 12853711
4. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.  |  Brenner, B. and Wiis, J. 2007. Hematology. 12: 55-62. PMID: 17364994
5. Liver transplant for congenital factor VII deficiency.  |  Acquazzino, MA., et al. 2014. Pediatr Blood Cancer. 61: 1886-7. PMID: 24585521
6. A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology.  |  de Vries, PS., et al. 2019. Blood. 133: 967-977. PMID: 30642921
7. A case of heterozygous factor VII deficiency in pregnancy.  |  Hasoon, J. and Rivers, JM. 2020. J Obstet Gynaecol. 40: 1025-1026. PMID: 31795789
8. Gilbert syndrome and factor-VII deficiency.  |  Seligsohn, U., et al. 1970. Lancet. 1: 1398. PMID: 4194152
9. Purification and properties of human coagulation factor VII.  |  Broze, GJ. and Majerus, PW. 1980. J Biol Chem. 255: 1242-7. PMID: 7354023
10. Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group.  |  Hellstern, P., et al. 1997. Vox Sang. 73: 155-61. PMID: 9358617

The preferred Factor VII antibody is Factor VII Antibody (CaFVII-22): sc-101369.